Protective͞suppressive major histocompatibility complex ( 
After the recognition of HLA DR2 as a haplotype negatively associated with type I diabetis and, therefore, protective against the disease (1), a number of protective major histocompatibility complex (MHC) class II genes have been identified in humans (2) and mice. In the mouse, I-E alleles have often been found to suppress antibody responses and are known to exert an ameliorating effect in collagen-induced arthritis (CIA), a disease that has an obligatory initial T helper type 2 (Th2) phase (3) (4) (5) . Recently, the I-A b allele has been found to be suppressive in CIA (5) and several antibody responses (6) while a suppressive effect of the H-2 b haplotype on IgG responses has been noted (7, 8) and may be part of the same phenomenon. In contrast, the I-A d and I-A k alleles are neutral, i.e., have not been found to exert a suppressive effect on antibody responses, whereas I-A q is a positive response gene in CIA and has not otherwise been tested for suppressive activity. All of these effects are dominant, in that the presence of a single copy of the gene is sufficient to obtain the suppressive͞protective effect (4, 9) . They represent no more than a bias, because each of these genes can also serve as a positive response gene for other antigens.
Differential expression of protective MHC class II molecules in the various antigen-presenting cells (APCs) is one hypothesis that has been proposed to explain the protective effect (2, 5, 10, 11) , although other possibilities remain open (3, 12) . The findings leading to the present study are as follows. An is responsible for heightened signaling in a macrophage cell line that is reversible by site-specific mutagenesis (13) . Early interleukin (IL) 4 transcription is strongly down-regulated in the presence of a single I-A b gene (9) , and anti-IL-4 mAb given early in the response mimics the protective͞suppressive effect of the gene (4). Thus, these findings suggest that the presence of an I-A b gene results in the release of a cytokine counter to IL-4, presumably IL-12. Meanwhile others have shown that ligation of class II molecules on macrophages elicits prompt release of IL-12, mainly via facilitated ligation of CD40 (14) ; the same effect can be obtained with monocytes (15) and dendritic cells (16, 17) , although there the IL-12 release may occur too late to account for the early suppression of IL-4 production. It therefore seemed likely that the level of expression of an MHC class II molecule might gate this back signal from a T cell to its APC so that heightened or more extensive expression would increase the IL-12 signal and thus exert a protective͞suppressive effect via Th1 bias (18) . To test this hypothesis, the expression of class II molecules from the four haplotypes H-2 b , H-2   d   ,  H-2   k , and H-2 q was measured on fresh splenic macrophages, on activated macrophages represented by bone marrowderived macrophages (BMDMs), on fresh splenic B cells, and on lipopolysaccharide (LPS)-activated splenic B cells. The latter cell type, known to show relatively high expression (19) and not expected to release an IL-4 counter cytokine (20) , served as a control. In addition, the cytokine responses of T cells restricted by protective, neutral, or disease-associated haplotypes were investigated. The data presented herein suggest that the differential MHC class II expression observed on BMDMs causes immune deviation among the responding T cells. Bone marrow cells from femurs were cultured (2 ϫ 10 5 cells per ml, 37°C, 5% CO 2 ͞95% air), in complete RPMI 1640 medium containing 10% fetal calf serum, 2 mM L-glutamine, penicillin (100 units͞ml), streptomycin (100 g͞ml), 5 ϫ 10 Ϫ5 M 2-mercaptoethanol, and 30% (vol͞vol) L-929 cellconditioned medium, to provide macrophage growth factor (21) . To eliminate contaminating fibroblasts, nonadherent bone marrow cells were transferred after 24 h to nontissue culture Petri dishes and grown in L929 cell-conditioned complete RPMI medium for up to 25 days. Adherent BMDMs were lifted by incubation in PBS containing 0.2% glucose (20 min, 37°C, 5% CO 2 ͞95% air) (22) . Single cell suspensions of spleens were depleted of erythrocytes by hypotonic lysis and were then used as a source for freshly isolated macrophages and B cells. Activated B cells were obtained culturing the single cell suspensions for 2 days in complete RPMI 1640 medium (37°C, 5% CO 2 ͞95% air) containing LPS (4.5 g͞ml). Analysis of the Anti-MHC Class II Antibody Binding Capacity of APCs. To measure the antibody binding capacity of the various APCs, biotinylated mouse IgG antibodies recognizing the different class II molecules were used in conjunction with Quantum Simply Cellular beads (Sigma) (24) . These beads are a mixture of four uniform microbead populations that differ in their incremental capacities to bind mouse IgG. The mean fluorescence values of the stained bead populations were used to calibrate the mean antibody-binding capacities (ABCs). The ABC of one cell directly reflects the mean number of surface MHC class II molecules.
MATERIALS AND METHODS

Mice
Analysis of the Cytokine Response of T Cells Restricted by Different MHC Class II Molecules. Mice were immunized s.c. at the tail base with 250 g of keyhole limpet hemocyanin (KLH) or chicken Ig (cIg) in Freund's complete adjuvant (25) . On day 7, the draining lymph nodes were isolated and endogenous APCs were depleted by magnetic cell sorting (MACS) using biotinylated anti-MHC class II antibodies and streptavidin-conjugated microbeads (Miltenyi Biotec, Sunnyvale, CA). The T cells were then restimulated in vitro, using KLH or cIg (250 g͞ml) plus 7-day-old BMDMs of either of the parental haplotypes as APCs. Intracellular cytokines were detected between 15 and 19 h later, with brefeldin A being added (10 g͞ml) to the cultures for the last 3 h (23). In detail, the cytokine production of the T cells was determined by triple stainings with three different colors and antibodies recognizing CD69, intracellular IFN-␥, and IL-4. The anti-cytokinespecific staining was blocked by incubating the cells with unlabeled anti-IL-4 antibodies (clone 11B11) at 25 g͞ml and anti-IFN-␥ antibodies (clone AN18.17.24) at 25 g͞ml for 15 min before staining with the corresponding fluorochromeconjugated antibodies. For isotype controls, we used phycoerythrin-and FITC-labeled rat IgG1 antibodies at 5 g͞ml.
RESULTS
Macrophages Retain I-A b and I-E k Molecules Longer. The expression of I-A molecules of the b, d, k, and q haplotypes and of I-E molecules of the k haplotype was analyzed on BMDMs cultured for up to 25 days. Fig. 1 shows the time courses of CD11b and H-2 expression as judged by mean fluorescence intensity (mfi). For all the BMDM cultures analyzed, CD11b expression showed similar kinetics in that it reached maximum expression around day 7 and then slowly declined (Fig. 1  Lower) . However, when comparing MHC class II expression, there were major differences (Fig. 1 Upper) . Expression of the protective͞suppressive I-A b and I-E k molecules on macrophages showed the slowest decline. Even after 19, 20, 24, or 25 days, respectively, there was still considerable I-A b and also I-E k expression as judged by mfi (Fig. 1 To quantify the differences in mfi observed for BMDMs stained with anti-MHC class II antibodies, the ABC was measured on day 7 at the height of MHC class II expression (see Fig. 1 ). For comparison, fresh splenic macrophages and fresh, as well as LPS-activated, splenic B cells were also analyzed. Among LPS-activated and fresh splenic B cells, the various haplotypes showed no more than a 2-fold difference in the estimated numbers of surface MHC II molecules (Fig. 2 ) and 677,000 (I-E k ), i.e., differences of 100-fold (see Fig. 2 ). Addition of LPS or phorbol 12-myristate 13-acetate at peak expression did not further increase MHC class II expression on these BMDMs (data not shown).
The molecules are expressed at a much lower level and the expression peaks for only about 1 day and then rapidly declines (see Fig. 1 ). The higher frequency and longer lasting expression found for these genes in macrophages is in agreement with the results obtained with promoter-reporter constructs in a macrophage cell line as mentioned above (13) . When comparing the MHC class II expression at peak level, there are about 100-fold more I-A effect. This bias is predicted by the hypothesis that a facilitated interaction between T cells and macrophages would increase IL-12 production (18) . Thus a pathway can be traced from a defined single-base promoter polymorphism, via extended expression of the class II gene, through a gating function of this expression, to the release of a counter-IL-4 cytokine, and so to a protective͞suppressive function.
The data obtained from BALB mice (Fig. 5 ) are less clear than those obtained from B.10 mice (Fig. 4) and disclose the variation to be expected. However, the results support the overall prediction that highly expressed alleles show a bias toward IFN-␥ and away from IL-4.
Whether the observed bias in cytokine production is introduced during the short immunization period or alternatively reflects a form of life-long immune deviation (27) Fig. 4 ). Extrapolating, this form of cross-talk might help explain the interaction of different susceptible, permissive, and protective HLA class II alleles observed in earlyonset pauciarticular juvenile chronic arthritis (28) .
The Th1 bias mediated by the I-A b allele was observed not only for both of the BALB and B10 mice but also for the two unrelated antigens. This argues against determinant selection (and its T cell receptor repertoire-biassing effect) as an explanation of the observations. It suggests that differential expression may play a role in the control of disease susceptibility by MHC class II genes. Differential expression is also in line with the distribution of polymorphism across MHC class II genes, which is high not only in the peptide-binding domains but also in the promoter region (promoter polymorphism is less evident in MHC class I genes) (2, 29) . Significantly, this polymorphism in the mouse is highest in the region of the X and Y boxes, where transcription factors bind; it has been suggested that heterozygosity in this region may confer increased fitness through immunological flexibility (29) . The extent to which this mechanism might operate in humans is uncertain; for instance, greater variation has been observed in class II expression on human B cells (30) .
It might seem surprising that IL-4 should exert a diseasepromoting effect in CIA, which has mainly been characterized as a Th1 disease (31, 32, † ) like its human counterpart rheumatoid arthritis (33) , and equally surprising that other animal models of autoimmune disease including type I diabetis, also characterized as a Th1 disease (34) , should show the same pattern of protection mediated by I-E. Evidently IL-4 has this effect only at the time of disease initiation in these animal models, as is known for CIA (4). The effect operates only at the time when IL-12 itself has a protective effect (31) . Besides CIA, another autoimmunity also inducible with adjuvant plus organ-specific antigen, experimental allergic uveitis, can be inhibited by IL-12 administered only during the early induction phase (35) . This paradoxical effect may reflect the poorly understood anti-proliferative and disease-inhibitory effects reported for INF-␥ (35, 36) and perhaps also the function of IL-4 as a growth factor for Th0 and Th1 cells (37) .
These data suggest that a highly expressed MHC class II molecule might exert its effect by facilitating CD40-CD40L ligation and thus enhancing IL-12 induction (18) . For this to occur, it is likely that the trimolecular complex of MHC molecule, antigenic peptide, and T cell receptor must form. Recent work suggests that the MHC molecule may also bind to the T cell receptor in an effective but apparently nonspecific manner (38) , possibly involving self peptides; this may deliver a survival signal to the T cell (39) (40) (41) . This apparently nonspecific signaling might account for the otherwise puzzling observation that the H-2A b molecule, although able to suppress the anti-allo-4-hydroxyphenylpyruvate dioxygenase (HPPD) response, does not bind the relevant allopeptide to a detectable extent (9) .
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